‘We anticipate continuing to build the portfolio and work together to bring the technology closer to commercialization.’ Surgical adhesions cause pain and dysfunction in an incredible number of patients worldwide. It is a complex inflammatory disorder in which tissues that normally stay separated in your body grow into one another, usually as a response of the tissues to surgical trauma. Currently marketed products for preventing surgical adhesions, such as films, gels and sprays, are both difficult to use and just marginally effective. ARC’s innovative technology combines ease of use, reduced surgery effectiveness and time period.. ARC Pharmaceuticals granted brand-new U.S. Patent ARC Pharmaceuticals Inc. announced today that The University of British Columbia provides been granted a new US patent entitled ‘Pharmaceutical Compositions and Methods Associated with Fucans, No.‘That is still a very big ‘perhaps,’ but probably at the time of a stroke, it might be beneficial, but just within the mind,’ Dr. Dorrance says of high aldosterone levels. ‘There is a huge caveat because aldosterone does not get into the mind terribly well.’ Other very good news emerging is definitely that adolesterone blockers, such as spironolactone and a more recent, more specific blocker eplerenone, can help switch the tide. Spironolactone was developed as an antihypertensive years ago but didn’t work very well, Dr. Dorrance says. After that, a University of Michigan research in the mid-1980s showed heart failure sufferers who got the drug in addition to standard treatment, such as beta ACE and blockers inhibitors, stopped dying basically, says Dr.